acetylcysteine eg 600 mg sachet
eg sa-nv - acetylcysteine 600 mg - oral powder - 600 mg - acetylcysteine 600 mg - acetylcysteine
acetylcysteine eg 600 mg efferv. tabl.
eg sa-nv - acetylcysteine 600 mg - effervescent tablet - 600 mg - acetylcysteine 600 mg - acetylcysteine
acetylcysteine eg 200 mg sachet
eg sa-nv - acetylcysteine 200 mg - oral powder - 200 mg - acetylcysteine 200 mg - acetylcysteine
acetylcysteine mylan 600 mg or. sol. (gran.) sachet
viatris gx bv-srl - acetylcysteine 600 mg - granules for oral solution - 600 mg - acetylcysteine 600 mg - acetylcysteine
acetylcysteine teva 600 mg sachet
teva pharma belgium sa-nv - acetylcysteine 600 mg - oral powder - 600 mg - acetylcysteine 600 mg - acetylcysteine
acetylcysteine teva 200 mg sachet
teva pharma belgium sa-nv - acetylcysteine 200 mg - oral powder - 200 mg - acetylcysteine 200 mg - acetylcysteine
acetylcysteine teva 600 mg efferv. tabl.
teva pharma belgium sa-nv - acetylcysteine 600 mg - effervescent tablet - 600 mg - acetylcysteine 600 mg - acetylcysteine
acetylsalicylic acid krka 100 mg gastro-resist. tabl.
krka d.d. novo mesto d.d. - acetylsalicylic acid 100 mg - gastro-resistant tablet - 100 mg - acetylsalicylic acid 100 mg - acetylsalicylic acid
acetylcysteine- acetylcysteine injection injection
exela pharma sciences, llc - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (rsi). acetylcysteine injection is contraindicated in patients with a previous hypersensitivity reaction to acetylcysteine [see warnings and precautions (5.1)] . risk summary limited published case reports and case series of pregnant women exposed to acetylcysteine during various trimesters are not sufficient to inform any drug associated risk. delaying treatment of acetaminophen overdose may increase the risk of maternal or fetal morbidity and mortality [see clinical considerations]. reproduction studies in rats and rabbits following oral administration of acetylcysteine during the period of organogenesis at doses similar to the total intravenous dose (based on the body surface area) did not cause any adverse effects to the fetus. the estimated background risk of major birth defects and mi
acetylcysteine injection, solution
sagent pharmaceuticals - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (rsi). acetylcysteine is contraindicated in patients with a previous hypersensitivity reaction to acetylcysteine [see warnings and precautions (5.1)] . risk summary limited published case reports and case series of pregnant women exposed to acetylcysteine during various trimesters are not sufficient to inform any drug associated risk. delaying treatment of acetaminophen overdose may increase the risk of maternal or fetal morbidity and mortality [see clinical considerations]. reproduction studies in rats and rabbits following oral administration of acetylcysteine during the period of organogenesis at doses similar to the total intravenous dose (based on the body surface area) did not cause any adverse effects to the fetus. the estimated background risk of major birth defects and miscarriage